Novalis LifeSciences collects $85 mln for inaugural fund

Novalis LifeSciences, an investment and advisory firm for the life science industry, has raised $85 million for its debut fund. Novalis LifeSciences Investments I LP will invest in eight to 12 companies “commercializing breakthrough technologies in various segments of the life science industry.”

PRESS RELEASE

HAMPTON, N.H.–(BUSINESS WIRE)–August 20th, 2019, Novalis LifeSciences, an investment and advisory firm for the Life Science industry, announced today that it has raised $85M in capital for its first fund – Novalis LifeSciences Investments I, L.P.

Novalis LifeSciences is focused on highly innovative Life Science companies. On the occasion of closing the first fund, Marijn E. Dekkers, founder and chairman, said: “This first fund is a growth-oriented fund that will invest in 8-12 companies that are commercializing breakthrough technologies in various segments of the Life Science industry. This includes drug discovery, life science tools, genomics, synthetic biology, diagnostics, and agricultural biotechnology – all areas with huge unmet needs and exciting opportunities for investors”.

About Novalis LifeSciences
Novalis Lifesciences LLC, is a globally acting venture capital firm focused on breakthrough technologies in Life Science. Founded and managed by Dr. Marijn E. Dekkers, current chairman of Unilever and former chief executive officer of Bayer AG and Thermo Fisher Scientific Inc., Novalis works with a diversified group of project-based specialists leading in their respective life science fields.

For more information please visit www.novalislifesciences.com or contact info@novalislifesciences.com